JPWO2022018171A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022018171A5 JPWO2022018171A5 JP2023504517A JP2023504517A JPWO2022018171A5 JP WO2022018171 A5 JPWO2022018171 A5 JP WO2022018171A5 JP 2023504517 A JP2023504517 A JP 2023504517A JP 2023504517 A JP2023504517 A JP 2023504517A JP WO2022018171 A5 JPWO2022018171 A5 JP WO2022018171A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- eef1a2
- polynucleotide sequence
- functional variant
- sequence encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055775P | 2020-07-23 | 2020-07-23 | |
| US63/055,775 | 2020-07-23 | ||
| PCT/EP2021/070455 WO2022018171A1 (en) | 2020-07-23 | 2021-07-21 | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535576A JP2023535576A (ja) | 2023-08-18 |
| JPWO2022018171A5 true JPWO2022018171A5 (https=) | 2024-07-30 |
| JP2023535576A5 JP2023535576A5 (https=) | 2024-07-30 |
Family
ID=71786970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504517A Pending JP2023535576A (ja) | 2020-07-23 | 2021-07-21 | ｅＥＦ１Ａ２の遺伝子治療ベクターおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230330265A1 (https=) |
| EP (1) | EP4185332A1 (https=) |
| JP (1) | JP2023535576A (https=) |
| KR (1) | KR20230039669A (https=) |
| CN (1) | CN116171325A (https=) |
| AU (1) | AU2021312320A1 (https=) |
| CA (1) | CA3186700A1 (https=) |
| IL (1) | IL299955A (https=) |
| MX (1) | MX2023000995A (https=) |
| WO (2) | WO2022017630A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3021572A1 (en) | 2016-04-20 | 2017-10-26 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Compositions and methods for enhanced gene expression of pklr |
| EP3697452A4 (en) | 2017-10-16 | 2021-11-24 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. | LENTIVIRAL VECTORS FOR ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFECTS |
| BR112020020841A2 (pt) | 2018-04-11 | 2021-01-19 | Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus | Composições e métodos para transplante de célulastronco |
| CA3096293A1 (en) | 2018-04-27 | 2019-10-31 | Rocket Pharmaceuticals, Ltd. | Gene therapy for cns degeneration |
| JP2023538519A (ja) | 2020-08-07 | 2023-09-08 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療 |
| WO2026006785A2 (en) * | 2024-06-28 | 2026-01-02 | Adverum Biotechnologies, Inc. | Melanopsin variants for vision restoration |
| WO2026044087A1 (en) | 2024-08-21 | 2026-02-26 | Shape Therapeutics Inc. | Increased cellular stability for aav production |
| WO2026073032A1 (en) | 2024-09-27 | 2026-04-02 | Shape Therapeutics Inc. | Constructs for improved aav production |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2187626C (en) | 1994-04-13 | 2009-11-03 | Michael G. Kaplitt | Aav-mediated delivery of dna to cells of the nervous system |
| CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| US7122350B2 (en) * | 2003-12-12 | 2006-10-17 | Zymogenetics, Inc. | Methods for enhancing expression of recombinant proteins |
| WO2009012176A2 (en) | 2007-07-14 | 2009-01-22 | The University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| JP2013523776A (ja) | 2010-04-02 | 2013-06-17 | セレジーン インコーポレイテッド | パーキンソン病および脳のドーパミン作動性ニューロンのその他の障害を処置する方法 |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
| IL248102B (en) | 2014-05-02 | 2022-07-01 | Genzyme Corp | aav vectors for gene therapy of the central nervous system and retina |
| CA3019315A1 (en) * | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
| AU2016324317A1 (en) * | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
| KR102423442B1 (ko) | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
| WO2020014523A1 (en) * | 2018-07-12 | 2020-01-16 | Rocket Pharmaceuticals, Ltd. | Gene therapy vectors for treatment of danon disease |
| CN113227126A (zh) * | 2018-11-26 | 2021-08-06 | 巴塞罗那自治大学 | 成纤维细胞生长因子21(fgf21)基因治疗 |
-
2020
- 2020-07-24 WO PCT/EP2020/071028 patent/WO2022017630A1/en not_active Ceased
-
2021
- 2021-07-21 KR KR1020237003445A patent/KR20230039669A/ko active Pending
- 2021-07-21 MX MX2023000995A patent/MX2023000995A/es unknown
- 2021-07-21 EP EP21755896.4A patent/EP4185332A1/en active Pending
- 2021-07-21 IL IL299955A patent/IL299955A/en unknown
- 2021-07-21 CN CN202180056421.4A patent/CN116171325A/zh active Pending
- 2021-07-21 WO PCT/EP2021/070455 patent/WO2022018171A1/en not_active Ceased
- 2021-07-21 AU AU2021312320A patent/AU2021312320A1/en active Pending
- 2021-07-21 JP JP2023504517A patent/JP2023535576A/ja active Pending
- 2021-07-21 CA CA3186700A patent/CA3186700A1/en active Pending
- 2021-07-21 US US18/017,502 patent/US20230330265A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021087431A5 (https=) | ||
| JP2021523718A5 (https=) | ||
| IL278213B1 (en) | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) | |
| JP2023088902A5 (https=) | ||
| JPWO2020106916A5 (https=) | ||
| JP2021533805A5 (https=) | ||
| RU2019139555A (ru) | Генная терапия нейрональных цероидных липофусцинозов | |
| JP2022501060A5 (https=) | ||
| JPWO2020033473A5 (https=) | ||
| JPWO2022018171A5 (https=) | ||
| JPWO2019222411A5 (https=) | ||
| WO2020236351A1 (en) | Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme | |
| AU2022386664A1 (en) | Materials and methods for slc6a1 gene therapy | |
| JPWO2021226267A5 (https=) | ||
| JPWO2020167996A5 (https=) | ||
| JPWO2021163556A5 (https=) | ||
| JPWO2022015715A5 (https=) | ||
| JPWO2022031756A5 (https=) | ||
| JPWO2021108809A5 (https=) | ||
| JP2025515356A5 (https=) | ||
| JPWO2021076911A5 (https=) | ||
| JPWO2020237130A5 (https=) | ||
| JPWO2023108029A5 (https=) | ||
| JPWO2023108129A5 (https=) | ||
| JPWO2023154763A5 (https=) |